Dr David Rosmarin (Tufts Medical Center, Boston, MA, USA) kindly took the time to speak with touchIMMUNOLOGY about the results from the safety and efficacy studies investigating ruxolitinib cream in vitiligo.
His presentation entitled ‘Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021.
- Could you tell us a little about the aims and design of the Phase 3 TRuE-V program?
- What have we learned so far from the 24-week data?
- What is the clinical significance of these findings?
- Which patients are likely to benefit most from ruxolitinib cream and in whom is it contraindicated?
- What will be the next steps towards regulatory approval for ruxolitinib cream in the treatment of vitiligo?
Disclosures: Dr David Rosmarin has received honoraria as a consultant for AbbVie, Abcuro, AltruBio, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceuticals, UCB, VielaBio; has received research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals Inc; and has served as a paid speaker for AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
Share this Video
Related Videos In Vitiligo
Thierry Passeron, EADV 2022: Efficacy of Ruxolitinib Cream by Body Region in Vitiligo – A Pooled Analysis of the TRuE-V Phase 3 Studies
TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies investigating ruxolitinib cream in adults and adolescents with vitiligo. touchIMMUNOLOGY were delighted to speak with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the rationale and findings from his pooled analysis looking at the effect of ruxolitinib cream on achievement […]
John E Harris, EADV 2021: JAK inhibitors and IL-15-targeted Therapies in Vitiligo
It was a pleasure to speak with Prof. John E Harris (University of Massachusetts Medical School, Worcester, MA, USA) about the use of JAK inhibitors in vitiligo, what we have learned from their discontinuation and how this has helped drive the development of IL-15-targeted therapies. His presentation entitled ‘Vitiligo: from topical JAK inhibitors to anti-IL15R’ […]
John E Harris, EADV 2021: New and Traditional Therapies for Vitiligo
As always, it was an honor to speak with Prof. John E Harris (University of Massachusetts Medical School, Worcester, MA, USA) about therapies, old and new, that have been used in the treatment of vitiligo. His presentation entitled ‘Vitiligo: from topical JAK inhibitors to anti-IL15R’ was given at the EADV 30th Congress, 29 Sep – […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!